Professional view

bisacodyl: prescribing and clinical use

Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.

bisacodyl: clinical details

Prescribing considerations

Exclude obstruction, an acute abdominal disorder or another cause requiring investigation.
Assess the underlying cause of repeated or ongoing laxative need.
Avoid prolonged excessive use because diarrhoea, dehydration, hypokalaemia and other electrolyte disturbances may occur.
Check the age restriction, legal category and excipients of the specific product.

Contraindications and cautions

Ileus or intestinal obstruction
Acute abdominal conditions, including appendicitis or acute inflammatory bowel disease
Severe abdominal pain with nausea or vomiting suggesting an acute abdominal condition
Severe dehydration
Hypersensitivity to bisacodyl or product excipients
For suppositories: anal fissure or ulcerative proctitis with mucosal damage
Product-specific hereditary excipient intolerances

Monitoring

Assess hydration and electrolytes after excessive use or clinically important fluid loss.
Consider electrolyte disturbance in patients taking diuretics, corticosteroids or cardiac glycosides.
Investigate persistent constipation, rectal bleeding, worsening symptoms or recurrent laxative reliance.

Clinical pharmacology

Bisacodyl is a locally acting diphenylmethane stimulant laxative. Enteric or mucosal hydrolysis forms BHPM, which stimulates colonic and rectal mucosa, promotes propulsive motility and increases water and electrolyte accumulation in the colonic lumen. Systemic absorption is limited, and the laxative effect does not correlate with plasma concentrations.

Formulation and product differences

Gastro-resistant tablets release bisacodyl in the lower gastrointestinal tract and must remain intact.
Suppositories act rectally and generally produce a faster effect than tablets.
Tablet licences differ by age: some are for people over 12, while adult-labelled products exclude those under 18.
Excipients vary: selected tablets may contain lactose, sucrose or colouring agents; SOVOLAX contains tartrazine, while the selected suppository uses hard fat.